Crossmark Global Holdings, Inc. Nektar Therapeutics Transaction History

Crossmark Global Holdings, Inc.

$5.23 Billion
Q2 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$3.04 - $5.14 $565 - $956	-186 Reduced 1.11%	16,614 $53,000
Q2 2022 Jul 29, 2022	SELL	$3.17 - $6.17 $8,346 - $16,245	-2,633 Reduced 13.55%	16,800 $63,000
Q1 2022 May 11, 2022	BUY	$4.16 - $13.72 $1,539 - $5,076	370 Added 1.94%	19,433 $104,000
Q4 2021 Jan 10, 2022	BUY	$10.83 - $18.41 $25,342 - $43,079	2,340 Added 13.99%	19,063 $258,000
Q3 2021 Oct 21, 2021	BUY	$13.07 - $18.84 $218,569 - $315,061	16,723 New	16,723 $300,000
Q3 2021 Oct 13, 2021	SELL	$13.07 - $18.84 $217,131 - $312,988	-16,613 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$16.52 - $20.4 $21,145 - $26,112	1,280 Added 8.35%	16,613 $285,000
Q1 2021 Apr 15, 2021	BUY	$16.56 - $25.46 $1,655 - $2,546	100 Added 0.66%	15,333 $307,000
Q4 2020 Jan 14, 2021	BUY	$15.77 - $19.03 $2,207 - $2,664	140 Added 0.93%	15,233 $259,000
Q3 2020 Oct 08, 2020	BUY	$16.59 - $24.79 $1,824 - $2,726	110 Added 0.73%	15,093 $250,000
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $16,910 - $23,510	1,003 Added 7.17%	14,983 $347,000
Q1 2020 Apr 28, 2020	SELL	$14.47 - $27.96 $8,971 - $17,335	-620 Reduced 4.25%	13,980 $249,000
Q4 2019 Feb 06, 2020	BUY	$15.87 - $23.12 $19,361 - $28,206	1,220 Added 9.12%	14,600 $315,000
Q3 2019 Oct 09, 2019	SELL	$16.91 - $36.27 $14,610 - $31,337	-864 Reduced 6.07%	13,380 $244,000
Q2 2019 Jul 09, 2019	BUY	$31.0 - $36.3 $9,331 - $10,926	301 Added 2.16%	14,244 $507,000
Q1 2019 May 02, 2019	BUY	$31.58 - $46.35 $9,474 - $13,905	300 Added 2.2%	13,943 $468,000
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $123,484 - $229,885	-4,058 Reduced 22.93%	13,643 $448,000
Q3 2018 Nov 08, 2018	SELL	$46.46 - $68.49 $418 - $616	-9 Reduced 0.05%	17,701 $1.08 Million
Q2 2018 Jul 31, 2018	BUY	$46.25 - $104.45 $174,131 - $393,254	3,765 Added 27.0%	17,710 $865,000
Q1 2018 Apr 16, 2018	SELL	$57.4 - $108.44 $931,200 - $1.76 Million	-16,223 Reduced 53.78%	13,945 $1.48 Million
Q4 2017 Feb 05, 2018	BUY	$23.02 - $60.5 $19,083 - $50,154	829 Added 2.83%	30,168 $1.8 Million
Q3 2016 Oct 25, 2017	BUY	N/A	29,339	29,339 $704,000

Others Institutions Holding NKTR

# of Institutions

140

Shares Held

135M

Call Options Held

32.8K

Put Options Held

55.5K

Deep Track Capital, LP Greenwich, CT

17.9M
Shares

$23.2 Million
0.73% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$19.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13M
Shares

$16.9 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.46M
Shares

$12.3 Million
0.21% of portfolio
Eventide Asset Management, LLC Boston, MA

7.53M
Shares

$9.79 Million
0.16% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account